Efficacy and safety of endoscopic prophylactic treatment with undiluted cyanoacrylate for gastric varices

Table 1 Demographic characteristics of patients n (%)

Characteristics	Patients (n = 20)
Mean age in years	47.35 ± 11.37
Male	15 (75)
Etiology
Viral	9 (45)
Alcohol	5 (25)
Schistosomiasis	2 (10)
Other	4 (20)
Child-Pugh class
A	13 (65)
B	7 (35)
Prior history of UGB	10 (50)
Eradication of EV	18 (90)
Propranolol use	12 (60)

UGB: Upper gastrointestinal bleeding; EV: Esophageal varices.

Table 2 Endoscopic characteristics of patients n (%)

Characteristics	Patients (n = 20)
GV Classification
GOV1	13 (65)
GOV2	3 (15)
IGV1	4 (20)
Form of GV
F1	7 (35)
F2 or F3	13 (65)
PHG
Mild	16 (80)
Severe	4 (20)
RCS	4 (20)

GV: Gastric varices; GOV1: Type 1 gastroesophageal varices; GOV2: Type 2 gastroesophageal varices; IGV1: Type 1 isolated gastric varices; PHG: Portal hypertensive gastropathy; RCS: Red color signs.

Table 3 Overall results of gastric varices treatment with cyanoacrylate injection n (%)

Characteristics	Patients (n = 20)
GV eradication	20 (100)
Number of sessions
1	13 (65)
2	7 (35)
Mean volume NBCM injected in mL	1.37 ± 0.48
Recurrence rate
3 mo	0
6 mo	1 (5)
> 2 yr	1 (5)
Total	2 (10)
Median follow-up in months (range)	31 (6-40)
Late bleeding rate	1 (5)
Minor adverse events1	3 (15)
Major adverse events	0
Overall mortality rate	0

¹Epigastric pain. GV: Gastric varices; NBCM: N-butyl-2 cyanoacrylate plus methacryloxysulfolane.